ArticleProceedings of the National Academy of Sciences of the United States of America2022
Intravesical delivery of
Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it, 146 citations in OpenAlex.
- Clinical benefit and risk of elemene in cancer patients undergoing chemotherapy: a systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Oxygen‑sensing histone demethylase KDM6A modulates chondrocyte‑to‑osteoblast transdifferentiation by activating the Wnt/β‑catenin pathway.International journal of molecular medicine · 2026Article
- The Nucleolus in Human Disease: Ribosome Biogenesis, Nucleolar Surveillance, and Therapeutic Opportunities.Biomolecules · 2026Review
- Advancements in delivery systems for in vivo chimeric antigen receptor T-cell therapy in urological diseases.Current urology · 2026Review
- Nanotechnology-mediated precision delivery of mRNA.Nature materials · 2026Review
- Nanotechnology-enabled precision strategies for bladder cancer: from in vitro diagnostics to in vivo therapy.Journal of nanobiotechnology · 2026Review
- Fully Wireless and Flexible Valves for Multiplexed and Prolonged Intravesical Liquid Release.Advanced healthcare materials · 2026Article
- Mucoadhesive tumor-penetrating nanomedicine for intravesical chemo-immunotherapy against bladder cancer.Science advances · 2026Article
- A worm-like nucleic acid nanostructure for gene delivery and endosomal escape via ClC3 ion exchanger.Science advances · 2026Article
- Nanoparticles co-loaded with bacillus Calmette-Guérin pure protein derivative and doxorubicin for bladder tumor therapy.BMC biotechnology · 2026Article
- Review
- Systemic reprogramming of tumour immunity via IL-10-mRNA nanoparticles.Nature nanotechnology · 2025Article
- miR-539-5p Regulates Irritable Bowel Syndrome Pathological Processes by Targeting KDM6A.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Developing Biomaterial-Based mRNA Delivery System for Lung Disease Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Review
- Recent Advances in mRNA Delivery Systems for Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Oral delivery of liquid mRNA therapeutics by an engineered capsule for treatment of preclinical intestinal disease.Science translational medicine · 2025Article
- Development of modern Chinese medicine guided by molecular compatibility theory.Journal of advanced research · 2025Review
- Using RNA therapeutics to promote healthy aging.Nature aging · 2025Review
- Synthetic Polymers for Drug, Gene, and Vaccine Delivery.Polymer science & technology (Washington, D.C.) · 2025Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on byUro-Science.2022
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lysine-specific demethylase 6A (KDM6A), also named UTX, is frequently mutated in bladder cancer (BCa). Although known as a tumor suppressor, KDM6A's therapeutic potential in the metastasis of BCa remains elusive. It also remains difficult to fulfill the effective up-regulation of KDM6A levels in bladder tumor tissues in situ to verify its potential in treating BCa metastasis. Here, we report a mucoadhesive messenger RNA (mRNA) nanoparticle (NP) strategy for the intravesical delivery of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.